This document discusses unrelated cord blood transplantation and the factors that affect outcomes. It notes that HLA mismatch level between donor and recipient impacts results, and that mismatches can be bidirectional. The document also addresses the two main pathways of T-cell regeneration, causes of secondary cytopenia after transplantation, and the current directions of using single transcription factors or expanding adult stem cells for transplantation purposes.
This document discusses unrelated cord blood transplantation and the factors that affect outcomes. It notes that HLA mismatch level between donor and recipient impacts results, and that mismatches can be bidirectional. The document also addresses the two main pathways of T-cell regeneration, causes of secondary cytopenia after transplantation, and the current directions of using single transcription factors or expanding adult stem cells for transplantation purposes.
This document discusses unrelated cord blood transplantation and the factors that affect outcomes. It notes that HLA mismatch level between donor and recipient impacts results, and that mismatches can be bidirectional. The document also addresses the two main pathways of T-cell regeneration, causes of secondary cytopenia after transplantation, and the current directions of using single transcription factors or expanding adult stem cells for transplantation purposes.
This document discusses unrelated cord blood transplantation and the factors that affect outcomes. It notes that HLA mismatch level between donor and recipient impacts results, and that mismatches can be bidirectional. The document also addresses the two main pathways of T-cell regeneration, causes of secondary cytopenia after transplantation, and the current directions of using single transcription factors or expanding adult stem cells for transplantation purposes.
Download as PPTX, PDF, TXT or read online from Scribd
Download as pptx, pdf, or txt
You are on page 1of 8
Transplants from Unrelated Donors
• Cord blood from unrelated donors has become an
important source of hematopoietic stem cells (HSCs). • The donor-recipient HLA mismatch level affects the outcome of unrelated cord blood transplantation. • Possible permissive mismatches involve the relationship between direction HLA mismatch vector or direction and transplantation outcomes. • In most cord blood transplants, a mismatched HLA antigen is present in recipient and donor. This type of mismatch is bidirectional between the graft and host. Two main pathways of T-cell regeneration • Thymopoiesis and peripheral blood expansion of mature T cells. • Thymopoiesis provides a new pool of naïve T cells that is essential for sustained long-term immunity. • Secondary cytopenia is a common complication of stem cell transplantation. • Causes of secondary cytopenia include viral infection, septicemia, GVHD, and myelotoxicdrugs. Current Directions • Consists of direct reprogramming of skin cells to a multipotent progenitor stage by the introduction of a single transcription factor, Oct4. • Another potential game-changing advancement would be the ability to reprogram human adult stem cells to an expandable condition without reducing the long- term self renewal properties and their safety. • The general goal of this field is transplanting donor stem cells to replace or repair defective cells in a patient. There are two critical concerns in the transplantation of umbilical cord blood: • 1. Initial time to engraftment 2. Restoration of immune function • The initial engraftment of cells that develop into the myeloid cell line (red blood cells, platelets, and granulocyte/monocyte) is 1 month. • Development of T- and B-lymphocytes commonly takes 6 months or more after transplantation. Two factors have been found to be of extreme importance: • 1.The total dose of progenitor (CD34+) cells in a cord blood unit has been associated with patient survival • 2.The total dose of clonogenic progenitors with the graft correlates with engraftment of the transplant. • To transplant stem cells into a fetus early in gestation. The benefit is that in utero transplantation would occur when the immune system of the fetus is immature, which would provide the theoretical opportunity to induce fetal tolerance of foreign cells. • This would avoid rejection and the need for immunosuppressive therapy.